Costimulatory signals regulate T-cell activation. To investigate the role of costimulation in autoimmunity and transplantation, we studied the BB rat model of type 1 diabetes. Diabetes-prone BB (BBDP) rats spontaneously develop disease when 55-120 days of age. We observed that two anti-CD28 monoclonal antibodies (mAb) with different functional activities completely prevented diabetes in BBDP rats. Anti-CD154 mAb delayed diabetes, whereas treatment with CTLA4-Ig or anti-CD80 mAb accelerated disease. Anti-CD86 or anti-CD134L mAbs had no effect. Diabetes resistant BB (BBDR) rats are disease-free, but >95% of them develop diabetes after treatment with polyinosinic-polycytidylic acid and an mAb that depletes Treg cells. In the induced BBDR model, anti-CD154 mAb delayed onset of diabetes, whereas CTLA4-Ig, anti-CD134L or either of the anti-CD28 mAbs had little or no effect. In contrast, blockade of the CD134-CD134L pathway was highly effective for preventing autoimmune recurrence against syngeneic islet grafts in diabetic BBDR hosts. Blockade of the CD40-CD154 pathway was also effective, but less so. These data suggest that the effectiveness of costimulation blockade in the treatment of type 1 diabetes is dependent on both the costimulatory pathway targeted and the mechanism of induction, stage, intensity and duration of the pathogenic process.

Autoimmunity, Diabetes, Rodent, Tolerance, Transplantation
dx.doi.org/10.1111/j.1600-6143.2005.01227.x, hdl.handle.net/1765/67730
American Journal of Transplantation
Erasmus MC: University Medical Center Rotterdam

Beaudette-Zlatanova, B.C, Whalen, B, Zipris, D, Yagita, K, Rozing, J, Groen, H.J.M, … A.A. Rossini. (2006). Costimulation and autoimmune diabetes in BB rats. American Journal of Transplantation, 6(5 I), 894–902. doi:10.1111/j.1600-6143.2005.01227.x